Why the study?
Does ouabain alter hemodynamic, volumetric, and metabolic parameters in patients with severe chronic coronary artery disease without heart failure?
Population
20 patients with severe chronic coronary artery disease without clinical congestive heart failure
Comparison
Ouabain (0.015 mg/kg body weight) infusion vs Identical protocol with omission of ouabain…
Design
Cohort
Follow-up
1 hour after infusion
Authors
Loading...
May reduce LV filling pressures in severe CAD without HF; leaves open clinical utility pending randomized trials.
Does ouabain alter hemodynamic, volumetric, and metabolic parameters in patients with severe chronic coronary artery disease without heart failure?
In patients with severe chronic CAD without heart failure, ouabain administration reduces left ventricular end-diastolic volume and pressure without causing a significant change in myocardial oxygen consumption.
DeMots et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: